Development of a UPLC-MS/MS method for the determination of sulfatinib and its no interaction with myricetin in rats
2024

New Method to Measure Sulfatinib and Its Interaction with Myricetin in Rats

Sample size: 10 publication Evidence: moderate

Author Information

Author(s): Chen Dongxin, Chen Jie, Xia Hailun, Chen Xiaohai, Hu Jinyu, Wu Guangliang, Xu Xuegu

Primary Institution: The First Affiliated Hospital of Wenzhou Medical University

Hypothesis

The study aims to develop a UPLC-MS/MS method for detecting sulfatinib and to investigate its interaction with myricetin in rats.

Conclusion

The study found no significant interaction between sulfatinib and myricetin in rats.

Supporting Evidence

  • The method demonstrated high linearity over a concentration range of 11–2,000 ng/mL.
  • The lower limit of quantification for sulfatinib was established at 1 ng/mL.
  • Pharmacokinetic parameters showed no significant differences when sulfatinib was administered with myricetin.

Takeaway

Researchers created a new way to measure a cancer drug called sulfatinib in rats and checked if it interacts with another substance called myricetin, but they found no interaction.

Methodology

The study used UPLC-MS/MS to quantitatively detect sulfatinib in rat plasma and assessed its interaction with myricetin.

Limitations

The study's findings may be limited by the small sample size and the doses of myricetin used.

Participant Demographics

Male Sprague-Dawley rats, weighing 200 ± 10 g.

Statistical Information

Statistical Significance

p>0.05

Digital Object Identifier (DOI)

10.3389/fphar.2024.1498339

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication